""If the U.S. is successful in equalizing prices [with other nations], we're going to lose a lot of the benefits that accrue from being that dominant payer." - Patrick Kilbride On day one of IPWatchdog's Life Sciences Masters 2025, panelists addressed a number of looming policy proposals that are negatively impacting the life sciences industry and urged stakeholders to get involved and speak out in order to minimize their effects."
"IPWatchdog Founder and CEO Gene Quinn, who was moderating, noted that such moves seem to be tied more to unrelated issues around purported antisemitism on campuses and combating "woke" ideologies, but the result is a lot of uncertainty in the meantime. "Universities are in a tough position," said Kaufman, as most need federal money. "It's shortsightedness from a national security standpoint. We're causing damage [in] an area where one of our most important geopolitical foes, China, is gaining," she added."
"A subsequent panel focused on providing a " Biopharma Law & Policy Update" and included Brent Bellows of Knowles IP Strategies, Patrick Kilbride of Kilbride Public Affairs and Peter-Anthony Pappas, Director of IP Policy for the U.S. Senate Judiciary Committee under Senator Thom Tillis (R-NC). Bellows told attendees that "the impacts on the industry are real. We see it every day." As an example, said Bellows, whereas a loss of exclusivity analysis for a client used to be "pretty basic and straightforward," that calculation has drastically changed today. "The policy issues""
Looming policy proposals, including a patent tax and threats to exercise march-in rights over federally funded university patents, are creating significant uncertainty for the life sciences sector. Federal actions tied to broader political issues risk disrupting university–industry technology transfer while geopolitical competitors like China advance. Proposed price equalization measures could erode benefits tied to the U.S. as a dominant payer and undermine innovation incentives. Changes in exclusivity and patent-value calculations are already altering commercial strategies. Increased stakeholder engagement and coordinated responses are needed to protect innovation, commercialization, and national security interests.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]